Latest News

We focus on local and international deals up to US$500 million in value across a wide range of sectors. Since the start of 2012 our partner firms have collectively completed over 230 deals, in 30 countries worldwide with an aggregate value of over US$17.5 billion.

Going Public Magazine interviews Stefan Constantin of C.H Reynolds on Biotech

10th May 2011

When thinking about M&A transactions in white biotechnology, there are some particularities that need to be observed as they don’t occur in other industries including red biotech.

GoingPublic magazine interview with Stefan Constantin, Partner, C H Reynolds Corporate Finance AG. Download the attached PDF at the bottom of page for the original article. When thinking about M&A transactions in white biotechnology, there are some particularities that need to be observed as they don’t occur in other industries including red biotech. M&A consultant Stefan Constantin from C.H Reynolds explains what matters when making deals in industrial biotechnology. GoingPublic: Mr Constantin, you executed several deals in the white biotechnology field. What are the particularities compared to other industries? Constantin: Generally, we are talking about technology transactions more than sales or profitability driven transactions. Often, the size of the target company is only a small fraction of the size of the buyer. The turn - over range of most targets lies between single-digit and double-digit millions, whereas buyers are often medium-sized or multi-billion companies. Another particularity is that the span of the potential buyers universe is much wider than in other industries. GoingPublic: Does this refer to industries as well as to company sizes? Constantin: Yes, but it also shows the different positions in the value chain. The range of interested companies varies from big chemical and pharmaceutical players producing patented consumer end products, generics, detergents, food supplements or scent and flavor substances to active ingredient (API-)manufacturers or medium-sized or big suppliers of inter mediates. Real Biotech-Competitors show interest in acquisitions as well although only few of them are financially strong enough to acquire. Depending on the development stage of the target company, corporate VCs are amongst the interested parties, too. GoingPublic: Is the acquisition of technology the main driver, or do competitive aspects also play a role? Constantin: As part of the sales process you have to bear in mind different aims for each interested group. Companies like Pfizer, Boehringer or Henkel as well as big suppliers are interested in the savings within their own production process, e.g. replacing three chemical steps by one organic step. Competitors are more interested in complementarity or in different technologies. GoingPublic: What exactly are the differences between the red and white biotechnology in terms of trans actions? Constantin: There are huge differences in relation to the structures of transactions: The white biotech business model is often wider in potential applications and contains out-licensing and co-operations with big companies already. The business models in the red biotech area are more focused with every clinical phase, leaving diagnostics and other red biotechs aside. As a consequence, the range of potential exit buyers rather gets smaller than bigger as the company progresses. Additionally, red biotech companies are ultimately bought when their development phase is coming to an end. In the area of oncology for example, there are in certain situations only five or six global players that can be considered as potential buyers. GoingPublic: Do white biotech companies have to reach a certain stage of development in order to raise interest, or is technology itself the main driver? Constantin: In contrast to the red biotech industry where each clinical phase reached limits products, and helps for the next financing round, even young white biotech companies can raise an enormous amount of interest. What matters is whether they are able to prove the functionality of their products in large scale areas. We think that at least two or three anchor projects in the context of co-operations or out-licensing with industrial partners are necessary to get the sales process going. GoingPublic: Which role do VC and Private Equity play in the early stage of financing as well as on the vendor side? Constantin: VC investors play a dominant role in financing. At a certain time, they are looking for exit possibilities. They have to support the management in their clear strategy in order to gain sufficient return on investment. Therefore company structures with regard to IP and sales force have to be positioned in such a way that they can be introduced into the market. In other words: Organizational support and strategic investments are needed. VC alone cannot always deliver that. Due to the sizes of investments, Private Equity rather plays a supporting role as developments in white biotech are part of their equity stories for the bigger investments like Cognis, Evonik or Süd-Chemie, being hold or held by Permira, CVC or OEP. In white biotech, Private Equity is rarely seen as direct buyer. GoingPublic: Even though VC-financing plays a dominant role, isn’t there a need to catch up in comparison to the red biotechnology? Constantin: Yes, absolutely. Playing a dominant role in this case does not necessarily mean: on a high level. In Europe and the U.S., there is only a limited number of VC-financed white biotech companies. Their number is rising, also due to cost pressure within the pharma/ chemical industry and the suppliers. This is underpinned by the increase in co-operations. GoingPublic: In Germany, white biotech has not yet entered the stock exchange … Constantin:We think that there are four reasons for this: First, we are talking about extremely complex products or processes that can be introduced into several application areas. Furthermore, the business model requires technology to be up-scaled on an industrial level which needs further investment. Additionally, the question arises where the company will position itself in three or four years when it “should” also deal with sectors like the food industry. Can the company sufficiently grow without an exit to a strategic partner? Or will it be taken over and vanish from the stock markets? The equity story is important: Chances and risks are difficult to communicate to the market. GoingPublic: When listed on the stock market, the capital market could offer a reasonable financing alternative … Constantin: This is generally true, but to a certain extent, it depends on customers and products. B.R.A.I.N, an intelligently and broadly positioned company, is often considered as a stock market candidate. But sales teams for the different segments adhesives, pharmaceuticals etc. have to be financed – potentially also using Venture Capital. Again, the question arises: Where does the company want to stand in four years? A supplier for big players? There are other companies beyond the mark of EUR 300 million in sales able to either develop white biotech by themselves or to acquire it. GoingPublic: How important is the international aspect for transactions in white biotech? Constantin: An international capacity is crucial for selling white biotech companies. We felt that in all our processes. Some companies don’t pay attention to this size of potential targets, e.g. suppliers of the pharmaceutical industry with a turnover of 300 to 400 million Euros which themselves have been thinking about getting involved with biotechnology but didn’t make it. Addressing international companies on a strategic level is essential for success. GoingPublic: Not only across the borders, but also across continents? Constantin: Absolutely. Just look at Indian generics producers: They are observing the German market very carefully. GoingPublic: Mr Constantin, thank you very much for this informative interview. 109-67a80a2de604bc6e39d314af987088dd.pdf
Adobe Acrobat file - 0.4 mb

< Back

latest opinion

Exploring Leveraged Recapitalizations as an Alternative to Selling a Business

Many owners of mid-sized private companies spend much of their working lives building a business yet ultimately reach a point where they seek to enjoy some of the financial rewards of their life-long efforts.…

Indian M&A: Can 2016 be turnaround year?

After 18% decline in M&A deals in 2015, corporates and investors are betting big on 2016.…

M&A in Dutch Digital market heating up

After a recovery of a few years M&A in the Dutch digital market is heating up. Aside from the traditional buyers (WPP, Publicis, Aegis and IPG) new platform companies have emerged such as Mediamonks, Oxyma and Tamtam. These companies, backed by large PE firms, are actively scanning the market to find additions to their product portfolio and we anticipate multiple transactions to be executed.…

2016 View from the US

The fundamentals that will drive M&A in the US and underpin US corporates’ appetite to acquire overseas in 2016 remain in place, despite the events of early January that have shown there are headwinds facing financial markets, resulting in significant volatility.…

A Manifest for Net Neutrality

For more than two decades all traffic in the internet was substantially treated equally (referred to as “net neutrality”).…

When Bad Things Happen to Good Companies: Seven Steps to Restoring a Company in Financial Distress

With volatility in today’s markets, the financial environment is unforgiving for faltering companies in the middle market.…

Call Connected: ATC buys 51% stake in Viom Networks for USD1.3b

In the largest inbound acquisition of FY16, American Tower Corp (ATC) announced acquisition of 51% stake in telecom tower infrastructure firm, Viom Networks. ATC will pay USD1.3b in cash and takeover debt of USD1b, valuing Viom at USD3.5b.…

Key Success Factors for a Management Buy-out

In a management buy-out (MBO) transaction the owner sells its company to the existing managers (the “MBO-team”) and their co-investor.…

Is Russia Stepping back from the Brink?

Since Russia openly challenged the post World War II order in forceably taking over Crimea and aiding rebels in Eastern Ukraine, it is clear that the Russian economy has suffered greatly due to a combination of low oil prices and Western sanctions.…

View more >

latest deals

Gerdau Aceros Europa - SIDENOR

The Spanish investor Clerbil, SL formed by the management team of Gerdau Aceros Europa acquired the European activities of the specialty steel producer of the…

Nana Oilfield Services - Project Landry

Headwaters MB announced today that it advised NANA Development Corporation on the sale of Nana Oilfield Services (NOSI) to Saltchuk Resources.

Project Landry kicked off…

Friendly Finance

Northstar advised Friendly Finance on the 80% sale of its shares to Finstar Group, a Russian finance company

Oogst - Tiger III

Capitalmind advised the shareholders of Oogst on the sale to Oxyma.

Oxyma, the first fully integrated omni-channel marketing agency in the Netherlands, has an active…

Aqualisa

RBS and Sankaty became majority shareholders of the business through a debt-for-equity swap in 2013 following a downturn in market conditions during the global financial…

SPPP - SPPP raises growth capital

Capitalmind advised SPPP Group on a fundraising underwritten by CITA Investissement to finance the group's development plan.

CITA Investissement invested as a minority shareholder along the…

Blondeau Group - acquires Boomex

Capitalmind advised the Blondeau Group on the acquisition of Boomex from its shareholders.

Operating 4 sites in Germany, the Boomex Group is a leading and well…

Texon International Group Ltd.

In 2010, Barclays Ventures (Barclays) assumed majority control of the business as a result of a restructuring. Since then, Barclays and the management team, led…

IS Group B.V. - IS - Redbee/Fortytwo

The acquisition of Redbee and Fortytwo by IS Group (subsidiary of KPN) is a next step to strenghten their position in the fast growing Dutch…

Onsite Health

Headwaters MB advised Onsite Health, a national leader in mobile medical and dental healthcare, on its sale to an undisclosed buyer.

Onsite Health’s multiple lines of…

b1 Engineering Solutions - Dot

b1 Engineering Solutions was part of Germany based multimedia group Blaupunkt. Blaupunkt group was formerly held by Aurelius who did not engage in any operational…

Toscotec S.p.A. - PROJECT PAPER

Ethica Corporate Finance advised the shareholders of Toscotec on the sale of the 40% stake to Synergo SGR, an Italian private equity firm focused on…

CBizz - CBizz funding

We have set up an investment fund of € 3m, funded by informal investors. The Fund invests in CBizz (acquired 10% of the shares) and…

Options Group

Barclays Ventures became the majority shareholder in 2009 following a debt for equity restructuring which also introduced a new management team who had a minority…

Doux - Terrena and Sofiproteol acquire Doux

Capitalmind Paris advised Terrena and Sofiprotéol (the investment arm of Avril group), two French leading agro-food companies in the acquisition of a majority stake in…

View more >